Medication Monitor



Generic Name (Trade Name—Company)
Notes
April 1, 2011

Varicella zoster vaccine, live, attenuated

(Zostavax—Merck)
Approved for use in younger patients

Uses:

Prevention of herpes zoster (shingles) in patients 50 to 59 years of age

Zostavax was originally approved for patients 60 years and older. Data from a placebo-controlled, double-blind study involving 22,439 patients who were 50 to 59 years of age showed that administration of the vaccine reduced the risk of developing zoster by 69.8% over a median monitoring period of 1.3 years. Injection-site reactions were the most commonly observed adverse events in this patient population.